A Phase 2 interventional study of Tau PET scan in Cognitive Impairment, sponsored by Mayo Clinic. Enrolling by invitation at 2 sites in United States. Open to participants aged 30 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by Mayo Clinic · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Cognitive Dysfunction by Mayo Clinic — 7 open to participants now, 9 under way, none of them phase 3. Cognitive Dysfunction · Mayo Clinic.
Among the 22 studies in Cognitive Dysfunction by Mayo Clinic, this one is the 3rd largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2018, is one of 5 in phase 2, and was the 8th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →7 of the 22 studies in Cognitive Dysfunction by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 50–90
Mayo Clinic · Sites in United States
Ages 18–100 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 40–90 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 40–90
By country, each count listing its studies:
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 30 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 4 2
First in 2009; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 42 across the 17 interventional studies, 71 across the 5 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
5 of the studies in Cognitive Dysfunction by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04785300Mayo ClinicALSENLITE: Senolytics for Alzheimer's Disease | 2026-12 |
| NCT01453127Mayo ClinicDaTSCAN Imaging in Aging and Neurodegenerative Disease | 2026-12 |
| NCT05514106Mayo ClinicMIBG in Aging and Neurologic Disorders | 2027-09 |
| NCT06029114Mayo ClinicMR Elastography of Cognitive Impairment | 2027-11 |
| NCT07331077Mayo ClinicA Physical Activity Program Compared to Health Education for Improving Memory and Attention in Hispanic Women With Newly-Diagnosed Stage I-IIIa Breast Cancer, MAMA Trial | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 22 studies in Cognitive Dysfunction by Mayo Clinic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The researchers are trying to gather information and learn more about imaging tests in racially different people who are cognitively normal or have dementia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cognitively normal volunteers
Combination Product: Tau PET scan
Person with cognitive impairment that meet Peterson Criteria
Combination Product: Tau PET scan
Patient's that meet dementia criteria
Combination Product: Tau PET scan
Patient will receive a dose of flutaucipir and be scanned appropriately
Tau positive scans
Percentage of each of the three groups with tau positive scans
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2018 (actual). Primary completion is estimated for May 2030, 138 months after the start.
Of 145 non-industry phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 64. This study's planned 138 months is above that.
Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.